LAV Biosciences Fund V L.P. 13D and 13G filings for Terns Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 5:21 pm Unchanged |
2023-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN |
LAV Biosciences Fund V L.P. | 2,901,566 4.700% |
0 (Unchanged) |
Filing |
| 2023-02-06 2:45 pm Sale |
2022-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN |
LAV Biosciences Fund V L.P. | 2,901,566 6.100% |
-63,304 (-2.14%) |
Filing |
| 2022-12-29 2:57 pm Sale |
2022-12-27 | 13G | Terns Pharmaceuticals, Inc. TERN |
LAV Biosciences Fund V L.P. | 2,964,870 6.180% |
-1,816,696 (-37.99%) |
Filing |
| 2022-02-09 12:29 pm Purchase |
2021-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN |
LAV Biosciences Fund V L.P. | 4,781,566 18.900% |
4,781,566 (New Position) |
Filing |